OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and ...

ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced its adoptive cell therapy, ELIAS Cancer Immunotherapy (ECI®), has received full approval from the U.S.

The Company reiterates its intention to submit a BLA with FDA for OST-HER2 in osteosarcoma in the second quarter of 2025, positioning it to receive approval in the fourth quarter of 2025. OST-HER2 has ...

Congressman and former Houston Mayor Sylvester Turner has died at the age of 70. In 2022, he was diagnosed with Osteosarcoma in his jaw.

Osteosarcoma (OS) is the most common primary malignant bone tumor in both humans and dogs. Canine and human OS share significant similarities in clinical presentation, histopathologic features, and ...

A malignant tumor, osteosarcoma, was diagnosed through CT (computed tomography) scans and pathological examination of biopsy samples. After two attempts at “tumor reduction surgery” with no ...

When she arrived at the hospital she was led into a room with seven medical professionals and the family was told an aggressive osteosarcoma was growing in Skyler’s right leg. “That’s when ...

"Our team has demonstrated the presence of SETDB1 abnormalities, particularly its amplification, through WES analysis of osteosarcoma human samples and cell lines." Authors Elodie Verdier, Nathalie ...

About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.